Davidson Eric, Obrosov Oleksandr, Coppey Lawrence, Yorek Mark
Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Department of Veterans Affairs Iowa City Health Care System, Iowa City, IA 52246, USA.
Biomedicines. 2025 Jun 30;13(7):1607. doi: 10.3390/biomedicines13071607.
: We have previously reported that omega-3 polyunsaturated fatty acids (PUFAs) derived from fish oil (FO) is an effective treatment for type 1 and type 2 diabetes neural and vascular complications. As omega-3 PUFAs become more widely used as a nutritional and disease modifying supplement an important question to be addressed is what is the preferred source of omega-3 PUFAs? : Using a type 2 diabetic rat model and early and late intervention protocols we examined the effect of dietary treatment with omega-3 PUFAs derived from menhaden (fish) oil (MO), krill oil (KO), algal oils consisting primarily of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or combination of EPA + DHA, or pharmaceutical-derived ethyl esters of EPA, DHA or combination of EPA + DHA. Nerve related endpoints included motor and sensory nerve conduction velocity, heat sensitivity of the hind paw, intraepidermal nerve density, cornea nerve fiber length, and cornea sensitivity. Vascular reactivity to acetylcholine and calcitonin gene-related peptide by epineurial arterioles that provide blood to the sciatic nerve was also examined. : The dose of each omega-3 PUFA supplement increased the content of EPA, docosapentaenoic acid (DPA), and/or DHA in red blood cell membranes, serum and liver. Diabetes caused a significant decrease of 30-50% of neural function and fiber occupancy of the skin and cornea and vascular reactivity. Treatment with MO, KO or the combination of EPA + DHA provided through algal oil or ethyl esters provided significant improvement of each neural endpoint and vascular function. Algal oil or ethyl ester of EPA alone was the least effective with algal oil or ethyl ester of DHA alone providing benefit that approached combination therapies for some endpoints. : We confirm that omega-3 PUFAs are an effective treatment for DPN and sources other than fish oil are similarly effective.
我们之前曾报道,鱼油(FO)中提取的ω-3多不饱和脂肪酸(PUFAs)是治疗1型和2型糖尿病神经及血管并发症的有效方法。随着ω-3 PUFAs作为一种营养和疾病改善补充剂被更广泛地使用,一个需要解决的重要问题是ω-3 PUFAs的最佳来源是什么?
使用2型糖尿病大鼠模型以及早期和晚期干预方案,我们研究了用来自鲱鱼油(MO)、磷虾油(KO)、主要由二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)或EPA + DHA组合而成的藻油,或药物衍生的EPA、DHA或EPA + DHA乙酯进行饮食治疗的效果。与神经相关的指标包括运动和感觉神经传导速度、后爪热敏感性、表皮内神经密度、角膜神经纤维长度和角膜敏感性。还检测了为坐骨神经供血的神经外膜小动脉对乙酰胆碱和降钙素基因相关肽的血管反应性。
每种ω-3 PUFA补充剂的剂量均增加了红细胞膜、血清和肝脏中EPA、二十二碳五烯酸(DPA)和/或DHA的含量。糖尿病导致神经功能以及皮肤和角膜的纤维占有率和血管反应性显著降低30 - 50%。通过藻油或乙酯提供的MO、KO或EPA + DHA组合治疗可显著改善每个神经指标和血管功能。单独的EPA藻油或乙酯效果最差,单独的DHA藻油或乙酯对某些指标的益处接近联合疗法。
我们证实,ω-3 PUFAs是治疗糖尿病周围神经病变的有效方法,鱼油以外的来源同样有效。